CSE:MYCO - Post Discussion
Post by
Betteryear2 on Mar 24, 2022 3:12pm
Conditional IRB Approval Phase 2b Smoking Cessation Study
DENVER, March 24, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced it has received conditional approval from the Institutional Review Board (IRB) for its multi-site Phase 2b smoking cessation trial. Johns Hopkins University will serve as the lead investigational site.
Be the first to comment on this post